| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
One of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic. [PubChem] |
| Indication |
Indicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs. |
| Pharmacology |
Trihexyphenidyl is an anticholinergic used in the symptomatic treatment of all etiologic groups of parkinsonism and drug induced extrapyramidal reactions (except tardive dyskinesia). Trihexyphenidyl possesses both anticholinergic and antihistaminic effects, although only the former has been established as therapeutically significant in the management of parkinsonism. |
| Toxicity |
Symptoms of overdose include mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particular in children. Premortal signs are respiratory depression and cardiac arrest. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
Trihexyphenidyl is rapidly absorbed from the gastrointestinal tract. |
| Half Life |
3.3-4.1 hours |
| External Links |
|